Physician profile
Evan Wilder
NPI 1487218087
$5,739.32
in general payments reported to CMS, 2019-2025
19 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $434 · 2023: $1,350 · 2024: $2,033 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,222 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,221.72 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,158.91 | 2022-2025 | Dupixent |
| Abbvie INC. | $975.84 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $910.62 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $465.74 | 2023-2025 | Voquezna |
| Genzyme Corporation | $452.86 | 2022-2025 | |
| Pfizer INC. | $331.01 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $327.76 | 2024-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $209.94 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $197.59 | 2023-2024 | Dificid, Zinplava, Prevymis |
| Regeneron Pharmaceuticals, INC. | $150.01 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $141.07 | 2022-2025 | Ocaliva |
| Janssen Biotech, INC. | $139.33 | 2024-2025 | Stelara, Tremfya |
| Mallinckrodt Hospital Products INC. | $104.76 | 2024 | Terlivaz |
| Ardelyx, INC. | $49.41 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $43.20 | 2023-2024 | Talicia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.57 | 2025 | Omvoh |
| Vivus LLC | $21.66 | 2024 | Qsymia |
| Celltrion USA INC. | $15.08 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $13.96 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.